In November 2015, the U.S. Food and Drug Administration (FDA) approved<unk>  for treatment of multiple myeloma in people who had received at least three prior therapies. In May 2016<unk>  was also conditionally approved by the European Medicines Agency for treatment of multiple myeloma. In November 2016, the FDA approved<unk>  in combination with lenalidomide or bortezomib and dexamethasone for the treatment of people with multiple myeloma who have received at least one prior therapy. In May 2018, the FDA expanded the approval of<unk>  for use in combination with bortezomib, melphalan and prednisone to include the treatment of people with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. The European Commission granted a marketing authorisation on 20 May 2016. In the European Union it is indicated as monotherapy for the treatment of adults with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
Daratumumab
Lanadelumab
Ofatumumab
Alirocumab
Tralokinumab
Olaratumab
Evinacumab
Ustekinumab